Curative or non-curative: immunotherapy for advanced melanoma
- Author(s)
- Kelly, R; Miller, A; Roberts-Thomson, R; Haydon, A;
- Journal Title
- JNCI Cancer Spectrum
- Publication Type
- Online publication before print
- Abstract
- Advanced melanoma was historically considered incurable, however a 52% 10-year melanoma-specific survival rate from seminal immunotherapy trials challenges that conclusion 1. There is no literature exploring clinicians' discussion of treatment-intent with patients, or whether this represents cure. We performed a multi-center retrospective cohort analysis to examine treatment-intent, using electronic medical records to identify 278 patients with unresectable or stage IV melanoma consented for immunotherapy from 2019-2023. 32 (12%) were consented for curative-intent treatment (CIT). CIT frequency was not significantly influenced by patient or disease characteristics. Patients consented for CIT received significantly higher rates of combination immunotherapy than patients consented for non-curative-intent treatment (NCIT), 76% (16/21) vs 47% (116/246), p 0.022. Among 267 unresectable patients, CIT rates differed significantly between Victoria and South Australia, 14% (20/142) vs 0.8% (1/125), p < .001. Our data confirms variability of documented treatment-intent in advanced melanoma. Further research is needed to understand how this impacts patients.
- Department(s)
- Medical Oncology
- Publisher's Version
- https://doi.org/10.1093/jncics/pkaf041
- Open Access at Publisher's Site
https://doi.org/10.1093/jncics/pkaf041- Terms of Use/Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2025-06-02 04:28:18
Last Modified: 2025-06-02 04:28:43